

Supplementary Fig. S1


a

Healthy control

polyarticular JIA


Kawasaki Disease

systemic-onset
JIA





Supplementary Fig. S1a. Identification of CD45⁻CD71⁺GPA⁺ erythroid cells in peripheral blood mononuclear cells by flow cytometry. Representative data of a healthy control and each patient with polyarticular JIA, Kawasaki disease, or systemic-onset JIA. The number on the plots was the percentage in the mononuclear cell region. Abbreviations: JIA, juvenile idiopathic arthritis; FS, Forward scatter; SS, side scatter; GPA, Glycophorin A (CD235a).

Supplementary Fig. S1



Supplementary Fig. S1b. The percentage and absolute number of CD45⁺CD71⁺GPA⁺ erythroid cells in peripheral blood mononuclear cells among healthy control and patients with oligo/polyarticular JIA, KD, and SoJIA. Abbreviations: oligo/poly JIA; oligo/polyarticular juvenile idiopathic arthritis; KD, Kawasaki disease; SoJIA, systemic-onset juvenile idiopathic arthritis.

Supplementary Fig. S1




Supplementary Fig. S1c-d. (c) Schema of the transition of surface markers on erythroid precursor cells, CD36, CD71 and GPA, in erythroid differentiation. (d) The percentage of CD45-CD36⁺CD71⁺GPA⁺ early erythroid cells and CD45-CD36⁻CD71⁺GPA⁺ late erythroid cells in peripheral blood mononuclear cells among healthy control and patients with oligo/polyarticular JIA, KD, or SoJIA. Horizontal bar means average. Data are analyzed by the Mann-Whitney *U* test with the Bonferroni correction. **P* < 0.05; ***P* < 0.01; ****P* < 0.001. Abbreviations: oligo/poly JIA, oligo/polyarticular juvenile idiopathic arthritis; KD, Kawasaki disease; SoJIA, systemic-onset juvenile idiopathic arthritis; GPA, Glycophorin A (CD235a).

Supplementary Fig. S2

	WBC	CRP	Hb	RDW	Reticulocyte	Ferritin	Erythropoietin	Hepcidine	IL-18	IL-6	Galectin3	IL-18BP	sTNFR1	sTNFR2	IFN γ	G-CSF	GM-CSF	Number of PBCEC	Percentage of PBCEC
Duration of fever *	-0.23	0.02	-0.56	-0.04	-0.27	0.13	-0.13	0.34	0.53	-0.27	-0.09	0.15	0.02	0.46	0.07	-0.15	0.13	-0.17	-0.12
WBC **		0.67	-0.09	0.43	0.22	0.38	0.71	0.60	0.24	0.61	0.56	-0.05	0.67	0.21	-0.30	0.16	-0.24	0.49	0.61
CRP **		<.001	0.63	0.02	0.25	0.03	0.005	0.007	0.18	<.001	<.001	0.80	<.001	0.24	0.09	0.36	0.19	0.004	<.001
Hb **				0.06	0.15	-0.14	-0.33	-0.32	-0.21	0.25	0.06	-0.15	-0.19	-0.45	-0.04	0.00	-0.04	-0.05	-0.07
RDW **				0.74	0.42	0.43	0.25	0.18	0.24	0.17	0.75	0.41	0.30	0.009	0.81	1.00	0.80	0.76	0.70
Reticulocyte ***						-0.20	0.01	-0.52	-0.19	-0.06	0.06	-0.29	-0.08	-0.24	-0.24	-0.05	-0.11	0.12	0.05
Ferritin **						0.31	0.97	0.03	0.33	0.75	0.75	0.13	0.66	0.21	0.21	0.80	0.58	0.54	0.81
Erythropoietin ****								0.53	0.59	0.91	0.82	0.07	0.66	0.27	-0.17	0.29	-0.29	0.55	0.67
Hepcidine ****								0.054	0.03	<.001	<.001	0.81	0.01	0.34	0.56	0.32	0.31	0.04	0.009
IL-18 **									0.38	0.56	0.24	0.44	0.48	-0.01	0.27	-0.01	0.29	0.42	
IL-6 **									0.03	<.001	0.18	0.0098	0.0046	0.97	0.13	0.94	0.10	0.50	0.55
Galectin3 **											0.45	0.02	0.43	0.09	-0.07	0.58	0.00	0.50	0.55
IL-18BP **											0.009	0.92	0.01	0.61	0.70	<.001	0.98	0.003	<.001
sTNFR1 **											0.28	0.71	0.30	0.06	0.03	-0.23	0.15	0.30	
sTNFR2 **											0.11	<.001	0.08	0.75	0.85	0.19	0.39	0.08	
IFN- γ **													0.53	0.67	0.83	-0.01	-0.12	0.11	0.13
G-CSF **													0.0013	<.001	<.001	0.98	0.49	0.54	0.46
GM-CSF **														0.61	0.19	0.12	-0.35	0.26	0.37
Number of PBCEC **														<.001	0.28	0.52	0.042	0.14	0.03
Percentage of PBCEC **															0.37	0.26	0.01	0.17	0.24
															0.03	0.14	0.98	0.34	0.17
																0.10	0.20	-0.02	-0.04
																0.59	0.25	0.91	0.80
																	0.44	0.52	0.49
																	0.009	0.002	0.003
																		0.10	0.09
																		0.57	0.63
																			0.94
																			<.001


Supplementary Fig. S2. Pearson's correlations matrix between the number or percentage of PBCEC and the continuous variables in patients with systemic-onset JIA, Kawasaki disease, or oligo/polyarticular JIA; * n = 0, 14, or 9, ** n = 10, 14 or 9; *** n = 9, 13, or 7; **** n = 3, 7, or 5. Upper and lower numbers in each matrix means Pearson's correlation coefficients (r) and P values. Shaded matrix indicates a significant association between two variables. Abbreviations: WBC, white blood cell; Hb, hemoglobin; IL-18BP, IL-18 binding protein; sTNFR, soluble TNF receptor; PBCEC, CD71⁺ erythroid cells in peripheral blood; RDW, Red cell distribution width.

Supplementary Fig. S3



Supplementary Fig. S3. The purity of CD45⁻CD71⁺GPA⁺ PBCECs sorted for the co-culture experiments.

Supplementary Fig. S4




Supplementary Fig. S4a-b. The levels of (a) TNF α and (b) interleukin-8 in the culture supernatant after the stimulation with lipopolysaccharide at 0, 10, and 100 ng/mL. Culture of healthy monocytes was performed without (left graph) or with peripheral CD71⁺ erythroid cells derived from SoJIA patients at the ratio of 1:0, 1:2, and 1:4 (right graph). The arginase inhibitor, amino-2-borono-6-hexanoic acid (ABH), was added to the culture medium at 0, 30, and 90 μ M.

Supplementary Fig. S4


c

Galectin-3



d

Interleukin-18 binding protein



Supplementary Fig. S4c-d. The levels of (c) galectin-3 and (d) interleukin-18 binding protein in the culture supernatant after the stimulation with lipopolysaccharide at 0, 10, and 100 ng/mL. Monocytes from healthy controls were co-cultured with PBCECs at the ratio of 1:0, 1:2, and 1:4. The experiment was repeated three times using PBCECs derived from three different patients and each culture was performed in triplicate. Data are representative of three independent experiments. Data are represented as mean \pm SD and analyzed by the Mann-Whitney *U* test with the Bonferroni correction. Error bars show standard error. Abbreviations: LPS, lipopolysaccharide; Mo: E ratio, the mixture ratio of healthy monocytes and patient-derived peripheral CD71⁺ erythroid cells.

Supplementary Table S1

Gene symbol	Gene ID	Fold differences compared to a healthy control			Gene information
		SoJIA	KD	HNL	
<i>AHSP</i>	AGhsB210214	11.10	2.33	0.72	Erythroid associated factor
<i>RAP1A</i>	AGhsC010919	11.77	3.36	1.06	Homo sapiens mRNA for Raichu404X
<i>HBD</i>	AGhsA040815	8.24	4.08	0.96	Hemoglobin, delta
<i>UROD</i>	AGhsB021218	7.94	3.39	1.15	Uroporphyrinogen decarboxylase
<i>MRPS7</i>	AGhsA150924	7.19	2.97	1.09	Mitochondrial ribosomal protein S7
<i>LRCH1</i>	AGhsB021205	7.15	2.05	0.95	Leucine-rich repeats and calponin homology domain containing 1
<i>CA1</i>	AGhsA191622	6.48	2.56	0.55	Carbonic anhydrase I
<i>ETS1</i>	AGhsA081020	6.20	2.10	1.06	V-ets erythroblastosis virus E26 oncogene homolog 1
<i>FGF7</i>	AGhsC081320	7.01	1.53	1.07	Fibroblast growth factor 7
<i>TCRDV1J1</i>	AGhsC080416	5.87	2.35	0.94	Homo sapiens T-cell receptor delta chain
<i>C19orf26</i>	AGhsC010813	5.87	1.51	0.96	
<i>C14orf131</i>	AGhsA161624	5.71	1.54	1.29	Chromosome 14 open reading frame 131
<i>VIPR2</i>	AGhsA201419	4.91	1.85	1.02	Hypothetical protein LOC154822
<i>TCN1</i>	AGhsA180813	4.09	1.34	1.36	Transcobalamin I
<i>SNCA</i>	AGhsA020723	4.61	2.13	0.64	Synuclein, alpha
<i>CAMP</i>	AGhsA251203	3.59	0.83	1.17	Cathelicidin antimicrobial peptide
<i>PRODH</i>	AGhsC010804	4.46	1.79	1.06	Homo sapiens p53 induced protein
<i>KIAA1853</i>	AGhsC011216	4.59	1.37	0.99	KIAA1853 protein
<i>SPTBN4</i>	AGhsB050409	4.74	1.66	1.01	betaiv spectrin isoform sigma3
<i>IMPA2</i>	AGhsA141306	4.33	1.79	1.14	Inositol(myo)-1(or 4)-monophosphatase 2
<i>EPB42</i>	AGhsA160910	4.21	1.88	0.72	Erythrocyte membrane protein band 4.2
<i>SASH1</i>	AGhsB010122	3.92	1.81	1.05	
<i>LR8</i>	AGhsA201207	3.82	1.60	1.37	LR8 protein
<i>TENS1</i>	AGhsA051605	4.10	1.33	1.06	Tensin 3
<i>DEFA3</i>	AGhsA050803	2.74	1.02	0.23	Defensin, alpha 3, neutrophil-specific
<i>MAOB</i>	AGhsA120523	3.45	1.53	0.98	Monoamine oxidase B
<i>OPRL1</i>	AGhsA130505	3.48	1.46	0.92	Opiate receptor-like 1
<i>FKSG39</i>	AGhsB050117	3.63	1.37	0.87	Homo sapiens FKSG39
<i>TPO</i>	AGhsA110805	3.25	1.16	0.97	Thyroid peroxidase
<i>C14orf87</i>	AGhsB231409	2.89	1.38	1.35	Chromosome 14 open reading frame 87
<i>CEAL1</i>	AGhsB261113	3.22	1.18	0.97	Carcinoembryonic antigen-related cell adhesion molecule 19
<i>AMT</i>	AGhsA230817	3.01	1.22	1.00	Aminomethyltransferase
<i>TM4SF9</i>	AGhsB021520	2.76	0.98	0.85	transmembrane 4 superfamily
<i>NOVA1</i>	AGhsB150813	2.74	1.14	1.16	Neuro-oncological ventral antigen 1
<i>REPIN1</i>	AGhsA020604	3.09	1.05	1.13	Replication initiator 1
<i>PEA15</i>	AGhsA251414	2.28	1.07	0.97	Phosphoprotein enriched in astrocytes 15
<i>EFHC2</i>	AGhsA021015	2.57	0.81	0.89	Homo sapiens EF-hand domain (C-terminal) containing 2
<i>C14orf159</i>	AGhsB120516	2.37	0.97	0.98	Chromosome 14 open reading frame 159
<i>STMN4</i>	AGhsB261404	2.24	1.01	0.91	Stathmin-like 4

Upregulated genes with more than 2-fold difference in PBMCs obtained from patients with SoJIA (n=5) compared to those from patients with KD (n=3) and HNL (n=4) and a healthy donor. The data was obtained during our previous study.²⁷ HNL, histiocytic necrotizing lymphadenitis; KD, Kawasaki disease; SoJIA, systemic-onset juvenile idiopathic arthritis